Navigation Links
BioMS Medical Announces 2009 Year End Results
Date:3/16/2010

million or $0.01 per share for the previous year.

Revenue of $45.6 million was recorded for the year ended December 31, 2009 compared to $52.6 million for the year ended December 31, 2008. The revenue is the result of the amortization of the upfront payment and development milestone received from the agreement with Lilly. Investment income earned on funds invested for the year ended December 31, 2009 decreased to $0.3 million from $2.4 million for 2008 due to the decrease in cash and cash equivalents. The investment income is earned from the short-term investment of cash reserves in low risk term deposits and bankers acceptance notes.

Total consolidated expenses for the year ended December 31, 2009 were $42.4 million compared with $61.9 million for 2008. Total consolidated expenses for the three months ended December 31, 2009 totaled $7.1 million as compared to $16.5 million in the same quarter the previous year.

Research a
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
2. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
3. BioMS Medical provides corporate update
4. BioMS Medical Announces Third Quarter 2009 Results
5. BioMS Medical announces second quarter 2009 results
6. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
7. BioMS Medical to participate in panel session at Bio International Convention 2009
8. BioMS Medical Announces First quarter 2009 results
9. BioMS Medical to present at Alberta Economic Forum in Geneva
10. BioMS Medical to present at BioFinance 2009
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Israel Biomedical Sensors Market - Growth, Trends ... The Israel Biomedical Sensors market is estimated ... 3.73% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with Down ... their day. The biotechnology company, located in the Science ... of the best potential therapies yet for people with Down ... " Correction of Down syndrome and Edwards syndrome aneuploidies ... DNA Research . Elixirgen plans to develop this ...
(Date:8/31/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... period following the filing of the Company,s Investigational ... U.S. Food and Drug Administration (FDA) has passed ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2New Down syndrome therapy discovered 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... April 20 Quark Pharmaceuticals, Inc., a development-stage ... (RNAi)-based therapeutics, today announced that James D. Thompson, ... presentation on Tuesday, April 20 at this year,s ... Annual Meeting, which is taking place from April ...
... COPENHAGEN, April 20 Santaris Pharma announced ... in vivo activity of microRNA-targeted,therapeutics against cancer ... Locked,Nucleic Acid (LNA) Drug Platform. In both ... cancer targeted LNA-antimiR(R),s demonstrated outstanding,recognition and inhibition ...
... 20 Mpex Pharmaceuticals, Inc. today announced that Mark Wiggins ... Wiggins comes to Mpex from Biogen Idec, Inc. where he ... and was a member of the Executive Committee. At ... development activities related to the company,s lead product, MP-376. ...
Cached Biology Technology:Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 2Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer 2Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer 3
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... sales campaign for Q4 2015. The new marketing campaign ... consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and ... is a leader in retail driven marketing and brand ...
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... have found a way to accurately predict the impact ... could result in better management strategies. The ... river temperature and salmon mortality rate, are published in ... Biochemical Zoology . While climate change and rising ...
... The National Institutes of Health has renewed a five-year ... an international biodiversity group lead by David G.I. Kingston, ... Kingston is known internationally for his work in ... with the Convention on Biological Diversity, he will share ...
... COLD SPRING HARBOR, N.Y. (Nov. 12, 2008) ... preparation for written exams on theoretical concepts, it can ... practical skills used in the clinic. The third ... prepare for these daunting practical-skills tests, Clinical Skills ...
Cached Biology News:UBC study establishes formula for predicting climate change impact on salmon stocks 2Chemist to donate potential pharmaceutical royalties to Madagascar 2New book helps medical students master clinical skills 2
Mouse Laminin-1 MAb (Clone AL-3)...
IEX-1 S/L (H-20)...
... reactivity with rat (100%), mouse ... pig (48%). Slight reactivity ... confirmed by Western blot versus ... Gia-1, Gia-2, rat Gia-3, bovine ...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: